Descrizione Clinica
DUCRAY
DEXYANE MED
Description
Treatment of eczemas of eyelids, atopics or contact. Milking from three months, children and adults.
Relieve immediately and decongestion.
It soothes itching and pain, reduces redness and irritations. Restore the skin barrier. Limit bacterial adhesion.
Mode of use
Apply 2 times a day a thin layer of product directly on the inflammatory lesions of eyelid eczema using a clean finger, avoiding any contact with eyes.
It can be used alone, in association and/or after use of topical corticosteroids. In case of association with a topical corticosteroid, apply the topical corticosteroid and wait a few minutes (5-15 minutes) before applying Dexyane MED Palpebre.
Components
Water (aqua), glycerin, caprylic/capric triglyceride, butylene glycol, polysorbate 60, glyceryl stearate, Butyrospermum parki (shea) butter, beeswax, PEG-100 stearate, 10-hydroxydecenoic acid, caprylynicl glycol, cetylten acid.
Warnings
Do not use in case of known allergy to one of the components. In the absence of data, do not use during pregnancy or breastfeeding. Only for external use. In case of allergic reactions, consult a doctor. Avoid direct contact with your eyes. Keep away from the reach of children. Close the pipe well after use.
Skin reactions can be manifested in the application area of the product (heat, itching, erythema, irritation, dryness) in the patient with eczema as it has an altered skin barrier. You can also see a temporary deterioration of eczema. In the absence of improvement or in case of worsening of the symptoms of eczema, in the following 8-10 days, consult a doctor. If you have any doubts and/or side effects related to the use of the product, consult a doctor. If you have a valid reason to believe that there has been a serious damage related to the use of the product, please contact the manufacturer immediately.
Conservation
Store at a temperature below 25 °C.
Post-opening validation: three months.
Format
15 ml tube.
Cod. THIS REGULATION SHALL BE BINDING IN ITS ENTIRETY AND DIRECTLY APPLICABLE IN ALL MEMBER STATES
Treatment of eczemas of eyelids, atopics or contact. Milking from three months, children and adults.
Relieve immediately and decongestion.
It soothes itching and pain, reduces redness and irritations. Restore the skin barrier. Limit bacterial adhesion.
Mode of use
Apply 2 times a day a thin layer of product directly on the inflammatory lesions of eyelid eczema using a clean finger, avoiding any contact with eyes.
It can be used alone, in association and/or after use of topical corticosteroids. In case of association with a topical corticosteroid, apply the topical corticosteroid and wait a few minutes (5-15 minutes) before applying Dexyane MED Palpebre.
Components
Water (aqua), glycerin, caprylic/capric triglyceride, butylene glycol, polysorbate 60, glyceryl stearate, Butyrospermum parki (shea) butter, beeswax, PEG-100 stearate, 10-hydroxydecenoic acid, caprylynicl glycol, cetylten acid.
Warnings
Do not use in case of known allergy to one of the components. In the absence of data, do not use during pregnancy or breastfeeding. Only for external use. In case of allergic reactions, consult a doctor. Avoid direct contact with your eyes. Keep away from the reach of children. Close the pipe well after use.
Skin reactions can be manifested in the application area of the product (heat, itching, erythema, irritation, dryness) in the patient with eczema as it has an altered skin barrier. You can also see a temporary deterioration of eczema. In the absence of improvement or in case of worsening of the symptoms of eczema, in the following 8-10 days, consult a doctor. If you have any doubts and/or side effects related to the use of the product, consult a doctor. If you have a valid reason to believe that there has been a serious damage related to the use of the product, please contact the manufacturer immediately.
Conservation
Store at a temperature below 25 °C.
Post-opening validation: three months.
Format
15 ml tube.
Cod. THIS REGULATION SHALL BE BINDING IN ITS ENTIRETY AND DIRECTLY APPLICABLE IN ALL MEMBER STATES
